Stock Detail
OXIGENE INC
Drugs
OXGN @ Yahoo Finance | OXGN Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $1.01 | $1.04 | $-0.03 | -2.88% | 0.00 | $1.04 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $1.02 | $0.99 | 348,273 | 14.82M | 718,390.5 | -2.20 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 1.06 | 1.03 | 1.01 | 0.98 | 0.96 |
Stock Profile
OXiGENE, Inc. engages in the research and development of products for the treatment of cancer and certain eye diseases. The company focuses on the development of products for application as direct cancer treatment agents, particularly vascular targeting agents (VTAs). It also investigates the use of certain products in the field of ophthalmology, in particular age-related macular degeneration and myopic macular degeneration. The company's technology, Combretastatin, is a family of proprietary small molecule anti-tumor VTAs. OXiGENE's CA4P compound targets the inner areas of the tumor. It is developing OXi4503 that targets blood vessels at the central core of the tumor, and appears to affect the vessels and tumor cells at the periphery. The CA4P is being tested in five human clinical trials in oncology, and one human clinical trial in ophthalmology. It is in Phase I/II combination clinical trial with Carboplatin and Paclitaxel in advanced ovarian cancer. In addition, a Phase II single agent trial in advanced and metastatic anaplastic thyroid carcinoma (ATC), and a Phase I/II combination trial in newly diagnosed ATC. OXiGENE is undertaking a Phase I/II combination trial with radiotherapy in head and neck, lung, and prostate cancers, as well as a Phase Ib combination trial with a monoclonal antibody in colorectal cancer. Its anti-tumor agent, OXi6197, reduces blood flow in newly formed tumor vasculature. The company is conducting Phase II single agent trial to treat a form of thyroid cancer, anaplastic thyroid carcinoma and a Phase II study for ATC to evaluate the mean survival time of patients. It is undertaking a Phase Ib study to evaluate the combination of CA4P with the radiolabeled anti-CEA monoclonal antibody A5B7. Additionally, the company has Phase I/II clinical trial for the nonlife threatening ocular disease, wet age-related macular degeneration. OXiGENE was incorporated in 1988 and is headquartered in Waltham, Massachusetts.